Nabriva Therapeutics plc - NBRV STOCK NEWS

Nabriva Therapeutics (NASDAQ: NBRV) announced positive topline results from a Phase 1 clinical trial assessing the safety and pharmacokinetics of XENLETA (lefamulin) in adult patients with cystic fibrosis (CF). The trial indicated that the pharmacokinetics in CF patients were consistent with previous studies involving healthy volunteers. XENLETA was well-tolerated, with an adverse event profile similar to previous studies. The results support XENLETA's potential utility in treating bacterial exacerbations in CF, particularly against Staphylococcus aureus, where treatment options are limited.

Nabriva Therapeutics (NBRV) reported Q3 2022 revenue of $9.2 million, up from $8.9 million in Q3 2021, driven by increased product sales of SIVEXTRO. The company is shifting its focus toward SIVEXTRO commercialization to extend its cash runway, which is now projected into Q1 2023. Nabriva took measures to reduce costs by approximately 40% in staff and suspended early-stage R&D activities. The net loss for Q3 2022 was $11.5 million, a slight increase from $10.7 million in Q3 2021. Nabriva engaged Torreya Capital for strategic advisory support.

Nabriva Therapeutics (NASDAQ: NBRV) will announce its third quarter financial results on November 10, 2022, post-market close. The company will host a conference call at 4:30 p.m. ET to discuss the results and provide highlights. Nabriva specializes in the development and commercialization of anti-infective agents, with key products including XENLETA for community-acquired bacterial pneumonia and CONTEPO for complicated urinary tract infections. Nabriva has an exclusive agreement with Merck for distributing SIVEXTRO in the U.S.

Nabriva Therapeutics plc (NASDAQ: NBRV) has announced a 1-for-25 reverse stock split effective September 16, 2022. This decision follows shareholder approval during the Annual General Meeting on August 11, 2022, aiming to comply with Nasdaq’s minimum $1.00 per share requirement. Post-split, the number of ordinary shares will decrease from approximately 69.7 million to about 2.8 million. The reverse split also affects authorized shares, reducing them from 300 million to 12 million. No fractional shares will be issued, and shareholders entitled to fractions will receive cash payments.

Nabriva Therapeutics (NASDAQ: NBRV) announced that CEO Ted Schroeder will give a company overview and business update at the H.C. Wainwright 24th Annual Global Investment Conference. This event is set for September 12-14, 2022, during which management will host investor meetings.

Nabriva is focused on developing innovative anti-infective agents. Their FDA-approved product, XENLETA^®, is the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia, while they are also developing CONTEPO™ for complicated urinary tract infections.

Nabriva Therapeutics has announced the completion of patient enrollment in its Phase 1 clinical trial assessing the safety and pharmacokinetics of XENLETA (lefamulin) for adults with cystic fibrosis (CF). The company anticipates reporting topline data in the first quarter of 2023. According to Dr. Christine Guico-Pabia, this study aims to evaluate XENLETA’s potential to manage bacterial infections in CF patients. XENLETA, a first-in-class antibiotic, may offer a new oral and intravenous treatment option for this challenging condition.

Nabriva Therapeutics (NASDAQ: NBRV) reported Q2 2022 revenues of $9.2 million, up 12.2% from $8.2 million in Q2 2021. Net product sales surged 25%, driven by a 28% increase in SIVEXTRO prescription demand. Research and development expenses rose 30% to $4.1 million, while SG&A expenses decreased by 14% to $11.0 million, leading to a net loss of $11.1 million, reduced from $11.8 million in the prior year. The company has sufficient cash to fund operations through Q4 2022 and announced a distribution agreement for XENLETA with Er-Kim Pharmaceuticals.

Nabriva Therapeutics plc (NASDAQ: NBRV) will report its second quarter financial results on August 3, 2022. The company focuses on developing innovative anti-infective agents, including XENLETA and SIVEXTRO. Nabriva has exclusive marketing rights for SIVEXTRO in the U.S. and has FDA approval for XENLETA, a first-in-class antibiotic for community-acquired bacterial pneumonia. The company will host a conference call at 4:30 p.m. ET following the earnings report to discuss these results and recent highlights.

Nabriva Therapeutics plc (NASDAQ: NBRV) has signed an exclusive Distribution Agreement with Er-Kim for the distribution of its antibiotic XENLETA (lefamulin) in several European countries. Er-Kim will manage distribution in Bulgaria, Croatia, Czechia, Greece, Hungary, Poland, Romania, Slovakia, and Slovenia, with rights to expand into five additional countries under a Named Patient Usage program. Nabriva aims to enhance the availability of XENLETA to treat community-acquired bacterial pneumonia (CABP), addressing significant unmet medical needs in these regions.